Health
Sequana Medical Announces First U.S. Commercial alfapump® Implantation at Mount Sinai Hospital in New York
Ghent, Belgium, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Milestone in bringing breakthrough treatment option to US patients with recurrent and refractory ascites due to liver cirrhosisFeedback from hepatology community supports US market potential from this large and growing market driven by obesityKey step in validation of Sequana Medical’s strategy of targeting US transplant centers through its specialty commercial teamContinued strong progress in US commercial roll-out Sequana Medical NV (Euronext B
About this update from Sequana Medical N.v
[{"type":"image","alt":"Sequana Medical NV","displaySize":"","headline":null,"caption":"Sequana Medical NV","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":64,"url":"https://media.zenfs.com/en/globenewswire.com/eebd983759ebc3a966954513471e9960"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/I6pT.8uzi87Vh1qGIu6GAg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTkwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/eebd983759ebc3a966954513471e9960","width":300,"height":64}},"lazy":false},{"type":"text","content":"Ghent, Belgium, Nov. 24, 2025 (GLOBE NEWSWIRE) --","length":49,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Milestone in bringing breakthrough treatment option to US patients with recurrent and refractory ascites due to liver cirrhosis","length":127,"tagName":"p"}]},{"val":[{"type":"text","content":"Feedback from hepatology community supports US market potential from this large and growing market driven by obesity","length":116,"tagName":"p"}]},{"val":[{"type":"text","content":"Key step in validation of Sequana Medical’s strategy of targeting US transplant centers through its specialty commercial team","length":125,"tagName":"p"}]},{"val":[{"type":"text","content":"Continued strong progress in US commercial roll-out","length":51,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":419,"olType":false},{"type":"text","content":"Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announced the successful completion of the first commercial implantation of the alfapump® System in the United States. This is a key milestone in Sequana Medical’s U.S commercial roll-out following receipt of Premarket Approval (PMA) from the FDA. The alfapump System is the first active implantable medical device approved in the U.S. for the treatment of recurrent or refractory ascites due to liver cirrhosis that automatically and continuously removes ascites fluid from the abdomen into the bladder.","length":697,"tagName":"p"},{"type":"text","content":"The successful implantation was completed at Mount Sinai Hospital in New York where the team specializes in advanced procedures for patients with liver disease. Sequana Medical is executing its focused commercializat...